In the latest trading session,, 6.29 million IGM Biosciences Inc (NASDAQ:IGMS) shares changed hands as the company’s beta touched 0.48. With the company’s most recent per share price at $1.31 changing hands around $0.19 or 16.96% at last look, the market valuation stands at $78.75M. IGMS’s current price is a discount, trading about -1617.56% off its 52-week high of $22.50. The share price had its 52-week low at $0.92, which suggests the last value was 29.77% up since then. When we look at IGM Biosciences Inc’s average trading volume, we note the 10-day average is 0.38 million shares, with the 3-month average coming to 212.80K.
Analysts gave the IGM Biosciences Inc (IGMS) stock a consensus recommendation rating of Hold, calculated at a mean rating of 4.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IGMS as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight.
IGM Biosciences Inc (NASDAQ:IGMS) trade information
Instantly IGMS is in green as seen in intraday trades today. With action 11.02%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -80.18%, with the 5-day performance at 11.02% in the green. However, in the 30-day time frame, IGM Biosciences Inc (NASDAQ:IGMS) is 3.15% up. Looking at the short shares, we see there were 0.72 million shares sold at short interest cover period of 3.55 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1.75, meaning bulls need an upside of 25.14% from its recent market value. According to analyst projections, IGMS’s forecast low is 1.5 with 2 as the target high. To hit the forecast high, the stock’s price needs a -52.67% plunge from its current level, while the stock would need to soar -14.5% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.57%. The 2025 estimates are for IGM Biosciences Inc earnings to increase by 59.57%, but the outlook for the next 5-year period is at 45.66% per year.
IGMS Dividends
IGM Biosciences Inc is expected to release its next quarterly earnings report on 2025-May-13.
IGM Biosciences Inc (NASDAQ:IGMS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 37.57% of IGM Biosciences Inc shares while 47.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.12%. There are 47.52% institutions holding the IGM Biosciences Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 6.7682% of the shares, roughly 4.09 million IGMS shares worth $28.1 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.743% or 4.08 million shares worth $28.0 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 448.61 shares estimated at $0.59 million under it, the former controlled 1.29% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.10% of the shares, roughly 381.7 shares worth around $0.51 million.
